Monday, October 3, 2022


Biotechnology News Magazine

Lipocine Reports FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system (“CNS”) disorders with high unmet medical needs, announced today that the U.S. Food and Drug Administration (“FDA”) has accepted the company’s Investigational New Drug Application (“IND”) for its neuroactive steroid (“NAS”) candidate, LPCN 2101, as a potential treatment for adults with epilepsy. Lipocine plans to initiate a Phase 2 photosensitive epilepsy (“PSE”) study to evaluate the safety, tolerability, and efficacy of oral LPCN 2101.

Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. commented, “We are excited to advance further testing of LPCN 2101. We believe it has the potential to address the unmet medical needs in epilepsy management as well as mood disorders comorbidities, particularly in women of childbearing age. We look forward to initiating the planned proof-of concept study.”

LPCN 2101 is an orally delivered, endogenous neuroactive steroid (“NAS”), a positive allosteric modulator (“PAM”) of GABAA receptor, with potential therapeutic effects in neurological and mood disorders. No concerning safety and tolerability signals were observed in the preclinical studies with LPCN 2101 while demonstrating a favorable pharmacokinetic profile.

About Phase 2 Photosensitive Epilepsy (“PSE”) Study Model

The photosensitivity study model enrolls patients who have an EEG-measurable photoparoxysmal response (“PPR”) triggered by light stimulation. Reduction in photosensitivity can be quantified after a single dose of a potential anti-seizure medication (“ASM”). Reportedly, positive results in the PSE model have proven to be a reliable marker of antiseizure efficacy for most approved ASMs.

About Women with Epilepsy: Epilepsy is a disorder of the brain that causes seizures. It is estimated that approximately 900,000 women of childbearing age suffer from active epilepsy in the U.S. These women with epilepsy of childbearing age face specific challenges throughout their lifespan because of seizures, efficacy and safety risks associated with the current ASMs, hormonal fluctuations, and coexisting mood disorders. Several currently available ASMs are teratogenic and have the potential to induce contraception failures, reproductive hormone imbalance, and mood disorders. There remains an unmet need for an ASM with no to low fetal-neonatal toxicity as well as potential to treat associated psychiatric comorbidities.

Lipocine is biopharmaceutical company leveraging its commercially validated proprietary technology to develop innovative products to treat metabolic and CNS disorders with high unmet medical need. Their candidates target diseases with potential for orphan drug designation, comprise endogenous actives for favorable benefit to risk profile, and represent enablement of patient friendly oral delivery options. Lipocine’s clinical development pipeline includes: LPCN 1148, LPCN 1144, LPCN 1111, LPCN 1107 and oral neuroactive steroids including LPCN 1154 and LPCN 2101.

TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the management of symptoms associated with liver cirrhosis. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating potential utility in the treatment of non-cirrhotic NASH. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

In a phase 2 clinical evaluation when administered as once or twice daily, LPCN 1111 met primary and secondary endpoints. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. Neuroactive steroids are currently being evaluated including LPCN 1154 for the potential treatment of postpartum depression and LPCN 2101 for the potential treatment of epilepsy.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine